(Q37274280)

English

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

scientific article published on 17 September 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 August 2017

0 references

1 reference

Europe PubMed Central

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer (English)

1 reference

Europe PubMed Central

19 August 2017

0 references

colorectal cancer

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Helena Linardou

1

1 reference

Europe PubMed Central

19 August 2017

Issa J Dahabreh

2

1 reference

Europe PubMed Central

19 August 2017

Dimitra Kanaloupiti

3

1 reference

Europe PubMed Central

19 August 2017

Fotios Siannis

4

1 reference

Europe PubMed Central

19 August 2017

Dimitrios Bafaloukos

5

1 reference

Europe PubMed Central

19 August 2017

Paris Kosmidis

6

1 reference

Europe PubMed Central

19 August 2017

Christos A Papadimitriou

7

1 reference

Europe PubMed Central

19 August 2017

Samuel Murray

8

1 reference

Europe PubMed Central

19 August 2017

publication date

17 September 2008

1 reference

Europe PubMed Central

19 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

19 August 2017

9

1 reference

Europe PubMed Central

19 August 2017

962-972

1 reference

Europe PubMed Central

19 August 2017

10

1 reference

Europe PubMed Central

19 August 2017

Gefitinib--a novel targeted approach to treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR and cancer prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor: mechanisms of activation and signalling.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor targeting in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR targeting of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab in the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Small molecules with EGFR-TK inhibitor activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective Study of Gefitinib in Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization–Positive/Phospho-Akt–Positive or Never Smoker Patients With Advanced Non–Small-Cell Lung Cancer: The ONCOBELL Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer genes and the pathways they control

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational analysis of gene families in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Determinants of RASistance to anti-epidermal growth factor receptor agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

FDA drug approval summary: panitumumab (Vectibix).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Diagnostic tests 4: likelihood ratios

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic versus predictive value of biomarkers in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A unification of models for meta-analysis of diagnostic accuracy studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Graphical presentation of diagnostic information.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab in the treatment of metastatic colorectal cancer: a model-based cost-effectiveness analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular selection of patients for first-line treatment of advanced non-small-cell lung cancer with epidermal growth factor inhibitors: not quite ready for prime time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

We should desist using RECIST, at least in GIST.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

RAF/RAS oncogenes and mismatch-repair status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2808%2970206-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(08)70206-7

1 reference

Europe PubMed Central

19 August 2017

1 reference

Europe PubMed Central

19 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37274280&oldid=1698884139"